Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
Haloperidol is a first-generation antipsychotic that compounding pharmacies prepare as oral liquids and topical gels, often with other agents, by prescription.
Haloperidol is a butyrophenone, a first-generation (typical) antipsychotic. It blocks dopamine D2 receptors in the brain, which is thought to account for its effects on psychosis, tics and nausea, with weaker effects on adrenergic, histamine and acetylcholine receptors. Manufactured haloperidol comes as tablets, an oral concentrate, a short-acting injection and a long-acting decanoate injection. The tablet label states it is FDA-approved for management of psychotic disorders, control of tics and vocal utterances in Tourette's disorder, and severe behavior problems or short-term hyperactivity in children when other treatments have failed. A prescriber might order compounded haloperidol in a topical gel combined with other anti-nausea agents for a patient who cannot swallow, as a flavored or preservative-free oral liquid, or at a strength not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Haloperidol carries an FDA boxed warning: elderly patients with dementia-related psychosis treated with antipsychotics have an increased risk of death, and haloperidol is not approved for that use. The label also warns of tardive dyskinesia (involuntary movements that may become permanent), neuroleptic malignant syndrome (fever, stiff muscles, confusion), QT prolongation with torsades de pointes and sudden death, low blood pressure, falls, heat stroke, pneumonia and low white blood cell counts. Do not use it if you have Parkinson's disease, severe CNS depression or coma, or an allergy to it. Lithium with haloperidol has caused brain injury in rare cases; rifampin lowers haloperidol levels; alcohol and sedatives add to drowsiness; other QT-prolonging drugs raise heart rhythm risk. The label says infants should not be nursed during treatment; LactMed reports low milk levels and advises watching the infant for drowsiness. Third-trimester exposure can cause movement or withdrawal symptoms in newborns. Call your prescriber right away for fever with stiff muscles, an irregular heartbeat, fainting or new abnormal movements; otherwise talk to your prescriber or pharmacist.
Haloperidol is a central D2 antagonist with lower affinity for alpha-1 adrenergic receptors and minimal muscarinic and H1 binding; sigma-1 and NMDA effects are proposed for its analgesic actions. Oral bioavailability is about 60% to 70% after first-pass metabolism, peak levels occur 2 to 6 hours post-dose, protein binding is about 89% to 93%, and half-life is roughly 13 to 35 hours with normal hepatic function. Metabolism is hepatic by glucuronidation, ketone reduction and CYP3A4, with a lesser CYP2D6 role; haloperidol itself inhibits CYP2D6. Labeled indications (haloperidol tablets, Mylan): psychotic disorders, Tourette's disorder, and pediatric severe behavior problems or hyperactivity after failure of other therapy. Prescribers have ordered compounded haloperidol in a topical gel with lorazepam and diphenhydramine (ABH gel) for nausea in hospice patients; a volunteer study found haloperidol and lorazepam undetectable in plasma after wrist application, so any effect is unexplained by systemic absorption (Smith et al., J Pain Symptom Manage 2012). The AHFS monograph lists delirium and chemotherapy-induced or postoperative nausea as off-label systemic uses. Dosing is per prescriber. Monitoring: QTc and electrolytes in at-risk patients, extrapyramidal symptoms, prolactin, CBC where baseline counts are low, and fall risk. Haloperidol is not a controlled substance.
Infusions are given only as your home infusion nurse or clinic has trained you. Before each infusion, check the label for your name, the medication, the dose and the beyond-use date, and inspect the bag for leaks, cracks or particles. Let a refrigerated bag come close to room temperature without heating it. Wash your hands, flush the line as directed, and call your nurse or provider right away for fever, chills, redness or swelling at the line, or leaking.
Sterile preparations carry a beyond-use date set under USP <797>; infusion bags are commonly stored refrigerated (2 to 8 C) and the label states the storage and the date. Keep bags out of reach of children and do not use a bag after its beyond-use date or if it looks damaged.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
